Thomas G. Wiggans

Thomas G. Wiggans (board member) discloses dealings in 4 companies, chiefly Dermira, Inc., Jasper Therapeutics, Inc. and Forma Therapeutics Holdings, Inc. Between 4 January 2016 and 22 September 2025, the trades on record add up to 14 filings.

The open-market side counts 6 purchases for €140k alongside 4 sales. No amount is published for 4 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 2 share grants. 2025 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €9,420. Of 6 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 24 September 2025, the filings show an open-market purchase worth €84k in Jasper Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.